Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing camidanlumab tesirine (ADCT-301) for relapsed or refractory Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Camidanlumab tesirine (camidanlumab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-03-28